Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose

Vaccine

Volumn 29, Issue 46, 2011, Pages 8459-8465

  Halperin, Scott A ^a   McNeil, Shelly ^a   Langley, Joanne ^a   Blatter, Mark ^b   Dionne, Marc ^c   Embree, Joanne ^d   Johnson, Roehl ^e   Latiolais, Thomas ^f   Meekison, William ^g   Noya, Francisco ^h   Senders, Shelly ⁱ   Zickler, Paul ^j   Johnson, David R ^k  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Primary Physicians Research Inc   (United States)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

^e The Jonesboro Children's Clinic   (United States)

^f Ark La Tex Children's Clinic   (United States)

^g Westcoast Clinical Research   (Canada)

^h MONTREAL CHILDREN S HOSPITAL   (Canada)

ⁱ University Heights ^*  (United States)

^j TASC CMX Research Services Inc   (Canada)

^k SANOFI PASTEUR   (France)

more..

Author keywords

Acellular pertussis vaccine; Adolescent immunization; Adult immunization; Diphtheria vaccine; Tetanus vaccine

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; TETANUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; REVACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTITOXINS; CANADA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; PAIN; UNITED STATES; YOUNG ADULT;

EID: 80053974825     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.068     Document Type: Article

References (40)

1. Galanis E., King A.S., Varughese P., Halperin S.A. Changing epidemiology and emerging risk groups for pertussis. CMAJ 2006, 174:451-452.
2. Brooks D.A., Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med 2006, 19:603-611.
3. Halperin S.A. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 2005, 24:S141-S146.
4. Cherry J.D. The present and future control of pertussis. Clin Infect Dis 2010, 51:663-667.
5. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishan G., Mannermaa L., et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Inf Dis 2010, 51:656-662.
6. National Advisory Committee on Immunization (NACI) Prevention of pertussis in adolescents and adults. Can Commun. Dis. Rep 2003, 29(ACS-5,6):1-9.
7. Centers for Disease Control and Prevention (CDC) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR Recomm Rep 2006, 55(RR-3):1-50. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
8. Centers for Disease Control and Prevention (CDC) Preventing tetanus, diphtheria, and pertussis among adults: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Recomm Rep 2006, 55(RR-17):1-37. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
9. Bailleux F., Coudeville L., Kolenc-Saban A., Bevilacqua J., Barreto L., André P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling. Vaccine 2008, 26:3903-3908.
10. Hallander H.O., Gustafsson L., Ljungman M., Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 2005, 23:5359-5364.
11. Booy R., Van Der Meeren O., Ng S.P., Celzo F., Ramakrishnan G., Jacquet J.M. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (BoostrixTM) is immunogenic and well tolerated in adults. Vaccine 2011, 29:45-50.
12. Sanofi Pasteur Limited. ADACELTM. Tdap vaccine: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed [Internet]. Silver Spring, MD: US Food and Drug Administration (FDA), Vaccines and Related Biological Products Advisory Committee (VRBPAC); 2005 February 15 [cited 2011 March 18]. Briefing Document No.: 2005-4097B1_6. p. 1-102. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1_6.pdf.
13. McNeil S.A., Noya F., Dionne M., Predy G., Meekison W., Ojah C., et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007, 25:3464-3474.
14. Ponvert C. Allergic and non-allergic hypersensitivity reactions to toxoid-containing vaccines. Arch Pédiatr 2009, 16:391-395.
15. Halperin S.A., Sweet L., Baxendale D., Neatby A., Rykers P., Smith B., et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 2006, 25:195-200.
16. Talbot E.A., Brown K.H., Kirkland K.B., Baughman A.L., Halperin S.A., Broder K.R. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010, 28:8001-8007.
17. Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. Safety of Tdap-IPV given one month after TD-IPV booster in healthy young adults. Human Vaccines 2009, 5:315-321.
18. Halperin S.A., Smith B., Russell M., Scheifele D., Mills E., Hasselback P., et al. Adult formulation of a five component acellular pertussis vaccine combined with diptheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immungenic in adolescents and adults. Pediatr Infect Dis J 2000, 19:246-283.
19. Waters V., Jamieson F., Richardson S.E., Finkelstein M., Wormsbecker A., Halperin S.A. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J 2009, 28:582-587.
20. Centers for Disease Control and Prevention (CDC) Use of mass Tdap vaccination to control an outbreak of pertussis in a high school-Cook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep 2008, 57:796-799.
21. Wei S.C., Tatti K., Cushing K., Rosen J., Brown K., Cassiday P., et al. Effectiveness of adolescent and adult tetanus, reduced-diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51:315-321.
22. de Greeff S.C., de Melker H.E., van Gageldonk P.G.M., Schellekens J.F.P., van der Klis F.R.M., Mollema L., et al. Seroprevalance of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010, 5:e14183.
23. Berger F., Njamkepo E., Minaberry S., Mayet A., Haus-Cheymol R., Verret C., et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. Vaccine 2010, 28:5147-5152.
24. Hochwald O., Bamberger E.S., Rubin L., Gershtein R., Srugo I. A pertussis outbreak among daycare children in Northern Israel: Who gets sick?. Isr Med Assoc J 2010, 12:283-286.
25. Baugh V., McCarthy N. Outbreak of Bordetella pertussis among oncology nurse specialists. Occup Med 2010, 60:401-405.
26. Jenkinson D. Duration of effectiveness of pertussis vaccine: Evidence from a 10 year community study. Brit Med J 1988, 296:612-614.
27. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
28. Barreto L., Guasparini R., Meekison W., Noya F., Young L., Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007, 25:8172-8179.
29. Sanofi Pasteur. Menactra® [product monograph] [Internet]. Toronto (ON): Sanofi Pasteur; 2008 September [cited 2011 March 18]. p. 1-41. Available from: https://www.vaccineshoppecanada.com/secure/pdfs/ca/menactra_e.pdf.
30. Gilberg S., Njamkepo E., du Châtelet I.P., Partouche H., Gueirard P., Ghasarossian C., et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002, 186:415-418.
31. Campins-Martí M., Cheng H.K., Forsyth K., Guiso N., Halperin S.A., Huang L.M., et al. International Consensus Group on Pertussis Immunisation Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001, 20:641-646.
32. Wirsing von König C.H., Halperin S.A., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
33. Andrews R., Herceg A., Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997, 21:145-148.
34. Forsyth K.D., Wirsing von König C.H., Tan T., Caro J., Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007, 25:2634-2642.
35. Frampton J.E., Keating G.M. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™). A review of its use as a single-dose booster immunization. Biodrugs 2006, 20:371-389.
36. Singhal T. Indian Academy of Pediatrics Committee on Immunization (IAPCOI) Consensus recommendations on immunization, 2008. Indian Pediatr 2008, 45:635-648.
37. de Carvalho A.P., Cesário Pereira E.M. Acellular pertussis vaccine for adolescents. J Pediatria 2006, 82:s15-s24.
38. World Health Organization (WHO). Regional consultation to standardize EPI schedule in the Eastern Mediterranean Region of the World Health Organization (WHO EMRO); 2006. Cairo, Egypt: VPI/EMRO; 2008 March 20 [cited 2011 March 18]. p. 1-23. Available from: http://www.who.int/immunization/sage/3_EMRO_1_EPI_Schedule_Report.pdf.
39. Bundesgesetz für gesundheit. Impfplan 2011 Österreich. [cited 2011 Apr 21]. Available from: http://www.bmg.gv.at/cms/home/attachments/7/3/0/CH1081/CMS1286449898381/impfplan_2011.pdf.
40. Calendrier vaccinal recommandé au Luxembourg. [cited 2011 April 21]. Available from: http://www.sante.public.lu/fr/rester-bonne-sante/vaccinations/calendrie.